Author(s): Miller N
Dengue virus (DENV) has four distinct serotypes. DENV infection can result in classic dengue fever and life-threatening dengue hemorrhagic fever/dengue shock syndrome. In recent decades, DENV infection has become an important public health concern in epidemic-prone areas. Vaccination is the most effective measure to prevent and control viral infections. However, several challenges impede the development of effective DENV vaccines, such as the lack of suitable animal models and the antibody-dependent enhancement phenomenon. Although no licensed DENV vaccine is available, significant progress has been made. This review summarizes candidate DENV vaccines from recent investigations.
Referred From: https://link.springer.com/article/10.1007/s12250-014-3542-7
Author(s): Sikka V, Chattu VK, Popli RK, Galwankar SC, Kelkar D, et al.
Author(s): Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, et al.
Author(s): Gubler DJ
Author(s): Centers for Disease Control and Prevention
Author(s): Centers for Disease Control and Prevention
Author(s): Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR
Author(s): Laemmli UK
Author(s): Waltz E
Author(s): Harrison WT
Author(s): Cox BD, Stanton RA, and Schinazi RF
Author(s): Kostyuchenko VA, Lim E, Zhang S, Fibriansah G, Ng TS, et al.
Author(s): Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH
